Pancreatic Cancer Research

ResearcherYokohama City University HospitalActive in the last 2 years

Shin Maeda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0246-1594; OpenAlex author ID A5017568301. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
66
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 19

  1. A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model. Co-author DOI 10.1111/cas.70246↗
  2. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  3. Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclit… Last author DOI 10.1016/j.esmogo.2025.100221↗
  4. Peritoneum carcinomatosis as a favourable prognostic factor for treatment with nanoliposomal irinotecan and fluorouracil plus leucovorin in advanced pancreatic… Last author DOI 10.1177/17588359251351540↗
  5. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study. Last author DOI 10.1007/s10147-023-02432-9↗
  6. Activation of STING in pancreatic cancer-associated fibroblasts exerts an antitumor effect by enhancing tumor immunity. Last author DOI 10.1038/s41598-024-68061-y↗
  7. Diagnostic Value of Contrast-Enhanced Dual-Energy Computed Tomography in the Pancreatic Parenchymal and Delayed Phases for Pancreatic Cancer. Co-author DOI 10.3390/tomography10100117↗
  8. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational… Last author DOI 10.1186/s12885-023-10654-3↗
  9. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysi… Last author DOI 10.1002/cam4.4512↗
  10. Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel. Last author DOI 10.1097/mpa.0000000000001985↗
  11. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus … Last author DOI 10.3892/ol.2022.13495↗
  12. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy. Last author DOI 10.1111/cas.14245↗
  13. A Novel Role of Interleukin 13 Receptor alpha2 in Perineural Invasion and its Association with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12051294↗
  14. Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis. Last author DOI 10.1007/s12328-019-00976-w↗
  15. Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pa… Last author PMID 30416859↗
  16. Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer. Co-author DOI 10.1111/cas.12080↗
  17. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2011.02053.x↗
  18. Covered stent placement for duodenal obstruction in pancreatic cancer. Co-author DOI 10.1159/000313695↗
  19. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci42754↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 8 shared papers, 2018–2026 · strength 1.29
  2. Satoshi Kobayashi · 7 shared papers, 2022–2026 · strength 1.22
  3. Manabu Morimoto · 7 shared papers, 2018–2025 · strength 1.08
  4. Yuichiro Tozuka · 7 shared papers, 2018–2025 · strength 0.99
  5. Junji Furuse · 4 shared papers, 2023–2026 · strength 0.80
  6. Shun Tezuka · 5 shared papers, 2018–2025 · strength 0.73
  7. Shuhei Nagashima · 4 shared papers, 2022–2024 · strength 0.66
  8. Itaru Endo · 4 shared papers, 2011–2026 · strength 0.56
  9. Makoto Sugimori · 4 shared papers, 2018–2025 · strength 0.55
  10. Yoshimasa Suzuki · 3 shared papers, 2020–2025 · strength 0.47
  11. Hiroyuki Asama · 3 shared papers, 2022 · strength 0.42
  12. Shingo Kato · 2 shared papers, 2011–2026 · strength 0.28
  13. Juri Ichikawa · 1 shared paper, 2026 · strength 0.26
  14. Yukihiko Hiroshima · 1 shared paper, 2026 · strength 0.26
  15. Tomohiko Tamura · 1 shared paper, 2026 · strength 0.26
  16. Kensuke Kubota · 3 shared papers, 2011–2024 · strength 0.23
  17. Noritoshi Kobayashi · 3 shared papers, 2011–2024 · strength 0.23
  18. Masaaki Murakawa · 1 shared paper, 2025 · strength 0.22
  19. Naoto Yamamoto · 1 shared paper, 2025 · strength 0.22
  20. Masanori Oshi · 1 shared paper, 2025 · strength 0.21
  21. Hajime Yamazaki · 1 shared paper, 2025 · strength 0.21
  22. Shinichi Ohkawa · 2 shared papers, 2018–2022 · strength 0.21
  23. Satoaki Nakamura · 1 shared paper, 2026 · strength 0.20
  24. Kentaro Yamazaki · 1 shared paper, 2026 · strength 0.20
  25. Yusuke Sano · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.